Despite large numbers of original research studies spanning 4 decades there is still no consensus on the subject of gestational diabetes. Should all pregnant women be screened or only those with risk factors? Or is it safe not to screen at all? Which screening test and which diagnostic test are the most reliable? Which cutoff values should we use? What are the risks involved for mother and baby and can treatment improve outcome? What is the connection between gestational diabetes and diabetes mellitus type II? Are there disadvantages to screening? A review of relevant articles shows that definitive answers to these questions are not yet available. There is no gold standard screening test and no threshold glucose value above which complications are markedly increased. On the contrary, there appears to be a continuum of slowly increasing risks with rising blood glucose values, where it seems difficult to draw a clear line between pathology and physiology. Moreover, treatment has thus far not been shown to significantly improve outcome. There seems to be an indistinct area between the diagnosis of gestational diabetes and diabetes mellitus type II, where women with risk factors for one are also predisposed to develop the other, thereby confusing the diagnosis. Finally, the disadvantages to diagnosing and treating women without a clearly proven benefit seem to be significant. Therefore it seems defensible to suspend all screening and treatment for gestational diabetes, or at least significantly raise the threshold for making a positive diagnosis and initiating treatment, until further research has proven a clear benefit.
possible explanation for this controversy is the fact that certain outcome parameters, such as fetal mortality, have become increasingly rare requiring clinical trials of very large size for definitive evaluation. Furthermore, screening for, and treatment of GDM have become so routine, that screening and treatment trials with an unscreened or treated control group may not be feasible. In daily practice it is difficult to find "the gold standard" in diagnosis and treatment. How do you prevent over treatment, or under treatment? What is supported by good evidence and what is not?
In this review we aim to discuss consecutively GDM diagnosis, incidence, risks, treatment, and pertinent international guidelines. We will also make an effort to recommend a practical approach to diagnosis, treatment, and follow up.
METHODS
We performed a MEDLINE database search with the words "gestational" and "diabetes" for articles published in English between 1993 and 2005.
Screening and Diagnosis
Many tests for GDM have been described over the past decades. A distinction is generally made between screening tests and diagnostic tests. A screening test can be performed on either a selective or a universal basis. Women with a positive screening test result continue with a diagnostic test, which is more extensive and demanding. In this way the prevalence of GDM in women undergoing the diagnostic test is higher, resulting in a higher positive predictive value. In general, screening and diagnosis are performed between 24 and 28 weeks because at this point in gestation the diabetogenic effect of pregnancy is manifest and there is sufficient time remaining in the pregnancy for therapy to exert its effects (10) .
Screening Tests
Several different screening tests are in use. The most widely used is screening for risk factors. If, during the first interview at booking, risk factors are found to be present, the woman will undergo a diagnostic test later in pregnancy. Screening for risk factors does not appear to be very reliable. The positive likelihood ratio is only 1.75, meaning that women with risk factors are only 1.75 times as likely to have GDM than those without (8) . A good screening test has a positive likelihood ratio of at least 6. Screening on the basis of risk factors seems to be inefficient (11) . In other words, a diagnostic test only in women with risk factors will miss many women with GDM and will unnecessarily subject many women without GDM to a diagnostic test.
Another screening test which is very widely used, is the 50 gram Glucose Challenge Test (GCT) (1, 4, 5, 7, 8) wherein the patient drinks a 50 gram glucose solution at a random time. Then a blood glucose measurement is taken after 1 or 2 hours, for which there are different cutoff values. The American Diabetes association recommends a cutoff value after 1 hour of either 140 mg/dL (7.8 mmol/L), which is said to identify 80% of women with GDM, or 130 mg/dL (7.2 mmol/L) which should identify 90% (12) . Weiner et al (13) compared the specificity of a one-hour test using a threshold of either 140 or 150 mg/dL (7.8 or 8.3 mmol/L) to a 2-hour test with a threshold of 118 mg/dL (6.6 mmol/L) and found that a 34% reduction in need for a diagnostic test would be achieved by using the 2-hour cutoff value, lowering the cost per patient identified by $200. Patients with a positive GCT are eligible for a diagnostic test. As with screening for risk factors, problems have also been reported for the GCT: there are many false-positives (4) and sensitivity is only 86% at best (14) .
Other screening tests are fasting blood glucose and random blood glucose. These tests are popular because they are easy to perform and not very demanding for the patient, but unfortunately there is lack of conclusive data documenting the reproducibility, sensitivity, and specificity of these tests (5) . On the other hand, some studies find that fasting glucose is reasonably reliable (15) , but it appears that some patients who are later found to have GDM exhibit elevated blood glucose levels only after a meal, with normal fasting levels. Furthermore, fasting glucose is known to be unreliable for predicting macrosomia in patients with diabetes mellitus type I (DMI) or II (16) .
Generally used cutoff values (derived from the screening for DMII) are 126 mg/dL (7.0 mmol/L) for fasting blood glucose and 200 mg/dL (11.1 mmol/L) for random blood glucose (5) . These are high enough that a diagnosis of GDM can be made without having to continue with a diagnostic test. Much lower cutoff values, starting from as low as 65 mg/dL (3.9 mmol/L) for fasting glucose have been recommended when screening for GDM (7) . Perruchini et al found that, when using a cutoff value of 85 mg/dL (4.8 mmol/L), an optimum in specificity and sensitivity was achieved of 76% and 81% respectively (15) . It has to be noted that fasting and random blood glu-cose values in the first half of pregnancy are on average a little lower than values for nonpregnant women (17) , while in the second half of pregnancy they are somewhat higher (7).
Other but not very commonly used screening tests are the glycosylated hemoglobin, capillary blood glucose measurement with a hemocue, breakfast tests, lunch tests, glycosuria, blood fructosamine, and the fetal Abdominal Circumference (fetal AC). Glycosylated hemoglobin appears to have a low sensitivity in pregnancy and is not to be recommended (18) . Capillary blood glucose measurements depend very much on the meter that is used and are generally not very reliable (19) . The breakfast and lunch tests have the advantage of using a standard test meal instead of an artificial glucose solution. The results seem to be reasonably reliable when performed with a standard (prescribed) meal (7), but have not been extensively researched and are not widely used worldwide. Glycosuria is notoriously unreliable since 73% of patients with glycosuria turn out not to have GDM (7), and blood fructosamine seems to have little value as a screening test on account of a very low sensitivity (20) . When using the fetal AC as a screening test, 43% of GDM patients will be left undiagnosed (21) . Moreover, the amount of benefit to be achieved from therapy when macrosomia has already occurred seems questionable.
Diagnostic Tests
The "gold standard" for diagnosing GDM has always been the 100 gram 3 hour Oral Glucose Tolerance Test (OGTT). This test was originally used to diagnose only "ordinary" diabetes (mainly type II) and has therefore been validated only for that clinical entity. When the test was first introduced for pregnant women it was hoped that it would distinguish those who were susceptible to contract DMII later in life, in order to be able to initiate early treatment. It was not meant to be used to prevent complications during the pregnancy itself (22) . The conditions for this test are very strict, and they do not represent a normal situation in day to day life: during the 3 days preceding the test the patient must have an intake of at least 150 grams of carbohydrates per day, and between 8 and 14 hours before the test is performed she is not allowed to eat or drink, except for water. No smoking is allowed during the 12 hours preceding the test. Before the first (fasting) glucose measurement the patient must rest for 30 minutes. After the first measurement, the patient drinks a 100 gram glucose solution. She has to finish this within the time limit of 5 minutes. One, 2 and 3 hours after finishing the drink, blood glucose measurements are taken. During these hours the patient is not allowed to smoke or walk. After the last measurement is taken, the patient has to eat something to prevent rebound hypoglycemia.
The original diagnostic cutoff values according to O'Sullivan and Mahan (23) were based on measurements in venous blood. Today blood glucose measurements are predominantly performed on plasma. The O'Sullivan criteria have therefore been converted to measurement in plasma; however, there are 2 separate conversions currently in use: the "Carpenter and Coustan (C&C) conversion" (24) and the "National Diabetes Data Group (NDDG) conversion" (22) ( Table 1) . Two abnormal values are needed for the diagnosis of GDM (23) . In the study by Magee et al (25) , there was a significant difference (up to 50%) in reported incidence of GDM, depending on which of the 2 conversions was used, while there was no discernable difference in perinatal outcome.
The biggest problem with this gold standard is that it is, in fact, not a gold standard at all. Reproducibility has been reported to be at best 78% (26) . One cause for this could be limited compliance by the patient, because the test conditions are so strict.
There has been movement to a lower glucose load. At present, the most commonly used OGTT internationally is the 75 gram glucose solution. This is the test recommended by the WHO (17) and it is used mainly outside the United States (Europe, Japan). In the United States the 100 gram OGTT is still predominantly used (Table 2) . (Table 1) . Unfortunately, this test is also said to be not very reproducible (7) . The same holds true for the 50 gram OGTT which is used in some Australian hospitals (27) .
Another commonly used test is the glucose day curve (GDC), in which several measurements are taken at fixed intervals during the day (after meals), without prescribing any specific meal or glucose load. The most widely used cutoff values with this test are 100 mg/dL (5.5 mmol/L) for fasting and 126 mg/dL (7.0 mmol/L) for random blood glucose. The GDC is predominantly used for evaluating the effects of therapy for GDM, but can also be used as a diagnostic test.
Lately, abnormal test results on any diagnostic test have been more and more divided into 2 groups: impaired glucose tolerance (IGT) and "true" GDM. The theory is that most differences in maternal and perinatal outcome can be attributed to the relatively small number of women with significantly elevated blood glucose levels, whereas the large majority of women with marginally or moderately elevated levels have little or no increased risk of bad outcome at all (17) . Cutoff values for the 75 gram OGTT to distinguish between the 2 groups are a 2 hour value of between 140 and 200 mg/dL (7.8-11.0 mmol/L) for IGT, and 200 mg/dL (11.1 mmol/L) or more for GDM.
Incidence
The exact incidence of GDM is unknown. The percentages reported in the literature are variable, and depend very much on the characteristics of the population studied and the criteria used for the diagnosis. Ethnic origin and age seem to be especially important factors. One prospective observational study (28) divided the population into 2 groups based on the presence or absence of risk factors. The investigators arrived at an incidence of 2.4% in the low risk group and 3.2% in the high risk group, which was not a significant difference. When the population was divided into groups based on ethnic origin the incidence of GDM was 0.4% for Caucasian women, 1.5% for Black women, 3.5%-7.3% for Asian women, 4.4% for women from the Indian subcontinent, and as much as 16% for Native American women.
The reported incidence of GDM increases with maternal age: most studies have used 25 years as cutoff point. The incidences found were 0.4%-0.8% in women younger than 25 years and 4.3%-5.5% in women older than 25 years (11, 29, 30) .
When incidence is studied by country of origin, the United States report 3%-8% (31), with a trend of rising percentages in more recent publications. The United Kingdom reports an incidence of 2% (7) and Canada describes 3.8% (32) . The rising percentages in reported GDM may well be correlated with an epidemic of obesity in developed countries (2), especially in the United States. Another explanation for the increase in incidence in the United States could be the trend to lower cutoff values for diagnostic tests, or greater uptake of the screening tests.
Risk Factors
Many risk factors for GDM have been suggested. Therefore, most screening strategies for GDM make use of the presence or absence of risk factors. The risk factors most widely used are:
• Age over 25 (2,4 -7) or 30 (33) years old. This risk factor is used throughout the world and most countries use 25 years as a threshold.
• Body mass index (BMI) over 25 (34) or 27 (35) .
• Ethnic origin, generally interpreted to mean any non-Caucasian women (2,4 -7).
• DMI or II or GDM in a first degree relative (2,4 -7).
• Previous history of GDM (36) .
Less commonly mentioned risk factors are a woman's own birth weight being lower than 2500 grams (37) or below the 10th percentile (38), a previous macrosomic baby (2,5), a previous bad outcome of pregnancy, for instance stillbirth (2, 5) , and polyhydramnios and/or a suspected LGA fetus in the current pregnancy (39) .
Depending on which risk factors are used to select women to be tested for GDM, a maximum of 90% of women are deemed to be high risk (4) . If screening were based on the following risk factors: age over 25 years old, and/or BMI over 27, and/or non-Caucasian origin and/or positive family history for GDM or DM, Davey et al (40) found that only 0.6% of women with GDM would go undiagnosed. On the other hand, depending on the risk factors used, several other studies reported that when screening only women with risk factors for GDM, up to 43% of women with GDM would not have been diagnosed (29, 41) .
Therefore, it seems that predisposing factors for developing GDM are not helpful in developing a screening policy, especially considering the fact that the average age of pregnant women has risen quite significantly since the time most of the cited studies were carried out.
Risks of GDM for Mother and Fetus
The purpose of screening for GDM is to diagnose and treat patients as early in pregnancy as possible, thereby preventing complications possibly caused by elevated blood glucose levels in pregnancy. A number of pregnancy complications are thought to be caused by GDM.
Macrosomia
Macrosomia is one of the most commonly mentioned problems associated with GDM (1,4-9). However, not every study uses the same criteria for macrosomia. Many authors use a cutoff value for birth weight above the 90th percentile (9) or a birth weight of more than 4000 grams for macrosomia, but some use 4500 grams (42) .
The reported incidence of macrosomia (Ͼ4000 grams) in women with GDM is 16%-29% (43, 44) , as opposed to a 10% rate in women without GDM. On the other hand, GDM can not be the only factor responsible for macrosomic babies, since Spellacy et al (42) found that, of all the babies with a birth weight higher than 4500 grams, only 5% had a mother diagnosed with GDM. Another study reports that only 10% of all babies with a birth weight over 4000 grams had a mother with GDM (45).
Casey et al (46) also concluded that a maximum of 12% of macrosomia could be explained by maternal GDM. The rest was due to maternal age, weight, and parity.
Cesarean Delivery
Macrosomia is an intermediate outcome, which in itself is not damaging to mother or baby. However, with macrosomia there might be an increase in cesarean deliveries, instrumental deliveries (forceps and ventouse deliveries), birth trauma such as brachial plexus injury or clavicular fracture, or neonatal hypoglycemia.
Therefore, most authors mention an increase in cesarean deliveries as one of the most important complications of GDM. However, this may simply be a labeling effect: because a patient has been diagnosed with GDM the threshold for cesarean delivery may be lowered. Naylor et al (43) reported a cesarean rate of 30% in women with GDM, compared to 20% in controls in spite of the fact that treatment of the GDM had normalized birth weights.
Shoulder Dystocia and Birth Trauma
The increase in birth trauma in the offspring of women with GDM is thought to be caused by a higher rate of macrosomia, which predisposes to shoulder dystocia. Since shoulder dystocia is not in itself harmful to mother or baby, the discussion mainly revolves around its consequences, namely clavicular fractures and brachial plexus injuries.
The incidence of brachial plexus injury has been shown to be increased with increasing birth weight, operative vaginal delivery and the presence of glucose intolerance (47) . However, Perlow et al (48) found in a retrospective chart review that GDM was present in the mother in only 6% of the brachial plexus injuries. Furthermore, they report that in 84% of clavicular fractures no mention of shoulder dystocia was made in the medical records.
A brachial plexus injury is a very serious complication and can have permanent sequelae in 5%-22% of cases (49) . At the moment, this is one of the leading causes of malpractice allegations. However, the concept of prophylactic caesarean delivery as a means to prevent shoulder dystocia and therefore avoid brachial plexus injury has not been supported by either clinical or theoretic data (50). Rouse et al calculated in 1996 that, in diabetic women, 443 babies with an estimated birth weight over 4500 grams or 489 babies with an estimated birth weight over 4000 grams would have to be delivered by elective cesarean delivery to prevent one permanent brachial plexus injury. This would have then cost $930,000 or $880,000, respectively, for each case prevented (51). Therefore, although for an individual patient with a permanent brachial plexus injury a planned caesarean could have made a large difference in quality of life, for the population in general the benefits likely do not outweigh the disadvantages.
Neonatal Metabolic Problems
In GDM an increased rate of neonatal hypoglycemia, hyperbilirubinemia, hypocalcemia, and polycythemia is reported (52) . This is then said to cause an increase in admission to the Neonatal Intensive Care Unit (NICU). In a study by Jensen et al (53) an increased rate of hypoglycemia is reported of 24% in babies of mothers with GDM compared to 0% in negative controls. However, this was a retrospective study and could be suffering from bias, as
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Obstetrical and Gynecological Survey children of mothers with known GDM are much more likely to be tested for hypoglycemia than asymptomatic children of mothers without GDM. Furthermore, there is evidence that neonatal hypoglycemia is much more related to macrosomia per se than to maternal GDM (54).
The most important question is: do these metabolic problems really have any permanent negative consequences for the babies' long-term health? It appears that adequately treated hyperbilirubinemia probably has no lasting effects on the infant (55) . In addition, long-term damage due to neonatal hypoglycemia seems limited to those few cases with hypoglycemic seizures or recurrent hypoglycemia (56) . On the other hand, there are definite drawbacks to screening all asymptomatic babies of GDM mothers for metabolic disease: the inconvenience for staff and baby of repeated blood tests, the costs of these tests and the separation between mother and child due to an unnecessary admission to the NICU.
Perinatal Mortality
Perinatal mortality was originally considered to be the most important complication of GDM. Evidence to support this is mainly found in older literature (57) . However, these studies described relatively small numbers of patients and the difference was found only in patients over 25 years of age. Furthermore the increase in mortality was not affected by treatment of GDM. More recent and larger trials have not been able to confirm this increase (46) . To be able to find or rule out a significant difference in perinatal mortality between babies of mothers with GDM and negative controls, larger numbers of patients would need to be included in randomized trials.
Hypertension/Preeclampsia
GDM has been associated with an increase in hypertensive disorders but there is some inconsistency in this association and questions about whether it is causal in nature. One study found a 20% incidence of hypertensive disorders in GDM women compared to 11% in controls (53) . In contrast, Naylor et al, in the Toronto Tri-Hospital Gestational Diabetes Project, found only a 9% incidence of preeclampsia in untreated GDM (43) , which is comparable to the incidence reported in treated women with GDM and in women treated for DMII or type I Diabetes Mellitus (DMI) (58) . Therefore, treatment of GDM apparently does not reduce the incidence of hypertensive disorders in pregnancy. None of the trials mentioned above had corrected for age or maternal BMI, which are well established risk factors for hypertensive disorders in pregnancy. It seems more likely, then, that any increase in hypertension in GDM patients could be accounted for by the fact that their age and BMI predispose them to GDM as well as hypertension.
Other Complications Associated with GDM
It is unclear whether premature delivery is more common among women with GDM (4). The same holds true for third-and fourth degree perineal tears (59) . These complications are reported only rarely in articles dealing with GDM and the influence of GDM on their incidence is difficult to ascertain.
The strongest associations between GDM and adverse outcomes for mother and baby, i.e. perinatal mortality, macrosomia, hypertensive disorders, and cesarean sections, are found in a subgroup of women with extremely high blood glucose values (75-gram 2-hour glucose Ͼ200 mg/dL or 11.1 mmol/L) (60) . (61) did not find any differences in adverse outcomes between GDM women and negative controls, especially no difference in the incidence of macrosomia, neonatal hypoglycemia, and polycythemia.
Late Effects of GDM on Mother and Baby
The prevalence of DMII in women previously diagnosed with GDM is higher compared to those without GDM in their earlier pregnancies (23) . Catalano et al (62) found that 22% of women who had GDM still had elevated blood glucose levels at 6 weeks post delivery. The reported prevalence of DMII later in life for GDM women varies from 9% in Caucasian women to 25% in Asian women, 47% in Hispanics, and as much as 70% in Canadian aboriginals (63) (64) (65) .
In a follow up study in a population of Hungarian women Tamas et al (3) found a prevalence of DMII of 42% eight years post delivery. An additional 7% had glucose intolerance. The risk was found to be higher in women for whom it had been deemed necessary to prescribe insulin during their pregnancy. However, women who have been previously diagnosed with GDM are much more likely to be tested for DMII in later life, so that screening bias could be present.
There is no evidence that treating GDM in pregnancy decreases the risk of later developing DMII.
However, the children of mothers with GDM are also at risk for DMII and obesity later in life (66) . Occasionally an increased risk for neuropsychological problems has been reported in these children (67) .
Treatment
As mentioned before, there is substantial controversy surrounding the criteria for diagnosing GDM. There is somewhat more consensus about the appropriate treatment once diagnosis is made.
The first step is usually a diet prescribed by a dietician. The goal is to limit intake of carbohydrates to 35%-40% of daily caloric intake. In patients with a BMI over 30 the target is to lower caloric intake by 30%-33% to about 25 kilocalories per kilogram of body weight (1) . The danger of limiting caloric intake too much is ketosis in the mother, which for her child has been associated with psychomotor retardation and low IQ (67) . Furthermore, the patient is advised to exercise more (68) .
If diet and exercise have not resulted in acceptable blood glucose levels, insulin is commonly prescribed. There is some consensus about the glucose levels above which insulin therapy is initiated. It is generally accepted to use the cutoff values recommended by the American Diabetic Association (ADA) (12): fasting 105 mg/dL (5.8 mmol/L), 1 hour after a meal 155 mg/dL (8.6 mmol/L) and 2 hours after a meal 130 mg/dL (7.2 mmol/L). Some studies recommend starting insulin therapy when the fetal AC measured by ultrasound is higher than the 75th percentile for gestational age (69) .
However, the target range for blood glucose values with insulin therapy is very narrow. In a study by Langer et al (70) , the incidence of macrosomic babies rose with random blood glucose values above 104 mg/dL (5.7 mmol/L), whereas the chance of Small for Gestational Age (SGA) babies increased with levels lower than 87 mg/dL (4.9 mmol/L), leaving a very small therapeutic margin.
The use of oral glucose lowering agents is currently being studied. Most of these can pass through the placenta and are therefore not deemed safe for use in pregnancy (12) . However, glyburide, an oral glucose lowering agent often used in the treatment of DMII, has been shown not to pass through the placenta and has been tested on pregnant women. So far, it appears safe for use in pregnancy (71), but considering the limited amount of evidence accumulated to date its use is not yet being recommended (6) . In one study it had a similar effect as insulin on blood glucose concentrations (72) .
Obviously, the ultimate therapy for GDM is delivery. Some authors advise induction of labor around 38 to 39 weeks in GDM patients using insulin, which in one study lowered the risk of shoulder dystocia from 10% to 1.4% (73) . A recent Cochrane Database meta-analysis, however, found a similar percentage of shoulder dystocia in the induction groups and the expectant management groups (74) .
Some studies recommend a cesarean delivery for women with GDM with an estimated fetal weight of more than 4000 or 4500 grams (51), or more than 5000 grams (42) . However, a recent cost-effectiveness analysis showed that in general, expectant management is the preferable approach, irrespective of estimated fetal weight (75) .
Does Treatment Improve Outcome?
The effect of treatment of GDM is the subject of a recent meta-analysis in the Cochrane Database (9). However, only 3 studies were included, due to very strict methodological criteria for inclusion. Of these 3 studies, 2 compared diet alone to diet and insulin and only 1 compared any treatment to no treatment at all.
In the meta-analysis, no difference in outcome was found regarding the percentage of cesarean sections, NICU admissions or the incidence of macrosomia (fetal weight greater than the 90th percentile). In treated patients, a relative risk (RR) of 0.55 (95% confidence interval (CI) 0.19-1.61) for macrosomia was observed, but this difference was not significant. The only statistically significant difference between the treatment groups and the control groups was a lower incidence of neonatal hypoglycemia in the treatment group, RR 0.25 (95% CI 0.07-0.86).
However, when only taking into consideration the study by Langer et al (76) which compared diet and/or insulin with no treatment at all, the treatment group did show a significant reduction in macrosomic babies (RR 0.27, 95% CI 0.09-0.76) in addition to the aforementioned reduction in neonatal hypoglycemia (RR 0.13, 95% CI 0.02-0.97). There was no observed difference in the number of cesarean sections (RR 0.82, 95% CI 0.36-1.84) or in the number of admissions to the NICU (RR 0.57, 95% CI 0.18-1.86).
Although these parameters were not included in the Cochrane meta-analysis, treatment of GDM has not been shown to reduce perinatal mortality (9) or the incidence of preeclampsia (5) .
An eagerly awaited study was the Australian Carbohydrate Intolerance Study in Pregnant Women (ACHOIS) trial (77) , which would finally answer the question whether there is a clear benefit to treatment of GDM over expectant management. Unfortunately, there is some concern about how women participating in this trial were selected. Results were collected over 10 years in 18 different hospitals, resulting in only 5 patients per hospital per year. Therefore, some selection bias may be present. Also, screening was not evaluated as part of the trial. This means that all women were screened and only those who met the criteria for GDM were randomized, so no women were left unscreened and therefore undiagnosed and there was no healthy control group.
Regrettably, the authors have yet again counted the occurrence of shoulder dystocia as a serious complication in itself, making the difference between the intervention group (7/506 serious complications) and the control group (23/524 serious complications) only just significant (P-value 0.04). Shoulder dystocia by itself should not be considered as an outcome parameter per se. There are no strict criteria for the definition of shoulder dystocia, and it is only the potential sequelae of shoulder dystocia, such as birth trauma, which matter. When we neglect shoulder dystocia as an outcome parameter in this study and look separately at outcome parameters such as the occurrence of birth trauma like bone fracture (0/506 versus 1/524, P-value 0.38) or nerve palsy (0/506 versus 3/524, P-value 0.11), two of which were in the same child, and perinatal death (0/506 versus 5/524, P-value 0.07), the difference between the two groups is no longer significant (0/506 versus 6/524 serious complications, P-value Ͼ0.06). Moreover, a substantially greater number of children in the treatment group were admitted to the NICU (357/506, 71%) compared to the control group (321/524, 61%), and a significantly larger number of women in the treatment group underwent an induction of labor (189/ 490, 39% versus 150/510, 29%), illustrating that the diagnosis and treatment of GDM may increase intervention without demonstrable benefit.
In conclusion, no randomized controlled clinical trial of sufficient sample size has been able to demonstrate conclusively that treatment of GDM (with diet and/or insulin) improves the outcome of pregnancy for mother or fetus. Most studies have methodological flaws or are too small to prove a significant difference. The only confirmed effect of treatment is a decrease in the incidence of neonatal hypoglycemia, with unclear importance for the baby's long-term prognosis.
Disadvantages of Diagnosis and Treatment
As stated previously, it is unclear whether screening for and treating GDM is beneficial. Nonetheless, this is considered standard practice all over the world. In the United States, at least 94% of gynecologists test all pregnant women for GDM (78) , without first screening for risk factors first. In Canada testing is also commonly performed, with 84% testing all pregnant women (5) . The other 16% (mainly in the Hamilton area), have suspended all screening practices and treatment, while awaiting definitive research. Percentages are significantly lower in the United Kingdom, where only 17% of the obstetrical caregivers screen all pregnant women, while 72% only test those with risk factors. Eleven percent have suspended all screening practices for the time being.
A telephone enquiry among all Dutch obstetric units (n ϭ 93), performed by the authors, shows that 66 units only test women with risk factors (with different tests). Eight units screen all patients at booking and those with risk factors are tested again later in pregnancy. Seventeen units screen all pregnant women at 24-28 weeks. In addition, 2 units are divided about screening practices and each gynecologist practices by his or her own protocol.
Considering the fact that no clear benefit of screening for and treating GDM has been proven to date, the question must be: are we doing more harm than good? There are several studies reporting a more negative perception of their own health by women diagnosed with GDM (79), or even by those who only had a false-positive screening test (80) , although other studies were unable to confirm this difference (81) or found a positive effect on mental wellbeing by a positive test for GDM (77) . The diagnostic tests (OGTTs) themselves are very demanding for the patients: up to 1.4% of women report vomiting during the 75 gram OGTT (82) , which rises to 4% for the 100 gram OGTT (83) . Other negative consequences of the diagnosis of GDM and subsequent treatment are: more medical interventions, for instance more cesarean deliveries (43) , ketosis after dieting (too strictly), which can cause more psychomotor development problems in the children (67), more SGA babies by too strict use of insulin (70) and of course higher public health costs.
Brody et al (4) calculated that, with an estimated incidence of GDM of 4% and treatment with insulin for 30% of these women, 8900 women have to be screened to prevent one brachial plexus injury, which in the majority of cases has no permanent sequelae.
CONCLUSION
Gestational diabetes was recognized and treated as a clinical entity, long before the principles of evidencebased medicine were developed (84) . In light of the recent scientific developments concerning trial protocols and interpreting their results it might be time to re-evaluate the approach to GDM and to adjust our protocols to current insights. Most of the recent review articles agree that 1) there is no consensus on whom to test, 2) there is no diagnostic gold standard and most tests are only moderately reproducible, 3) the risks of GDM for mother and baby are fairly minimal, and 4) the benefit of treatment for mother and baby is uncertain at best. There appears to be a continuum of slowly increasing risks with rising blood glucose values. The issue is likely to be further clouded by the fact that most trials concerning GDM do not screen for DMII at booking. Therefore, it is well possible that those women who have the worst outcome (and very often the most abnormal diagnostic tests) have in fact type II diabetes, predating their pregnancy.
It is difficult to make a clear recommendation regarding GDM without definitive data from well done randomized studies indicating benefit. Currently underway is the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) trial, financed by the National Institutes of Health, USA, which will compare treatment to expectant management.
At this time it seems justified to follow the advice of the Cochrane Database and suspend all screening and treatment except as part of a clinical study, while awaiting definitive data from large randomized controlled clinical trials.
Alternatively, it seems safe to adopt much higher cutoff values for treatment than used to date, as recommended by Health Technology Assessment UK (7), thereby treating only real diabetes and not IGT, considering the evidence for an association of unfavorable maternal and fetal outcomes with especially high blood glucose levels.
Also, there seems to be a clear benefit to using pregnancy as an early metabolic marker for the predisposition to develop DMII. Women who have been diagnosed with abnormal glucose levels during pregnancy should be offered screening for DMII on a yearly basis.
